Moderna has validated the druggability of neoantigen‑based therapeutics with the first positive Phase‑3 clinical result. Yet mRNA is merely one technical pathway. As industry focus shifts from “can this work therapeutically” to “how to make it accessible to patients worldwide”, peptide‑based vaccines are emerging as a viable alternative.
1. After Moderna: The Industry's Core Concerns Have Shifted
On August 19, Moderna and Merck announced that intismeran autogene (mRNA‑4157/V940), a personalized mRNA‑based vaccine, in combination with Keytruda, achieved dual co‑primary endpoints of recurrence‑free survival (RFS) and distant metastasis‑free survival (DMFS) in the Phase 3 INTerpath‑001 trials2.q4cdn.c.... On the day of the announcement, Moderna's stock price surged by 177%.
This marks the first positive Phase‑3 outcome for both individualized neoantigen therapy (INT) and mRNA‑based anti‑cancer therapeutics. It is also the first Phase‑3 study demonstrating clinically meaningful clinical benefit added on top of single‑agent Keytruda, the standard‑of‑care immunotherapy, in the adjuvant setting for resected melanoma. From a scientific standpoint, these results confirm that neoantigen therapeutics are clinically feasible. The “one‑patient‑one‑drug” personalized cancer vaccine is no longer merely a lab‑scale concept, but a therapeutic strategy validated in registrational‑grade clinical trials.
Nevertheless, a critical question arises: is mRNA the only viable path forward?
Intismeran autogene is an mRNA‑based individualized neoantigen therapy (INT). The full workflow from sample collection to final drug formulation takes approximately six weeks. During manufacturing, genetic sequencing is performed on patient‑matched tumor and normal tissue samples. AI algorithms identify immunogenic neoantigens from tumor mutations (up to 34 neoantigens are selected per patient). These neoantigens are encoded into mRNA molecules, encapsulated within lipid nanoparticles (LNPs), and administered back to patients to train T‑cells to recognize and attack residual cancer cells.
This modality has proven effective. However, as the industry seeks to expand its scope beyond melanoma to additional cancer types, substantial engineering‑related limitations of the mRNA platform have become unavoidable.
2. Addressing the Limitations of mRNA
2.1 Manufacturing Challenges for Personalized Vaccines
Conventional vaccines are mass‑produced identical products. By contrast, personalized vaccines require small‑batch production of innumerably distinct drug products. Each patient receives a unique vaccine; there exists no standard product. Every batch must independently complete the full workflow including sequencing, design, synthesis, and quality control.
Accordingly, mRNA‑based personalized vaccines face multi‑layer industrial bottlenecks. First, LNP manufacturing is technically complex. mRNA molecules are intrinsically unstable and require lipid‑nanoparticle encapsulation for effective delivery, and LNP production and QC themselves constitute a high technical barrier. Second, cold‑chain logistics impose strict constraints: mRNA drug products generally require ultra‑low‑temperature storage and transport, placing heavy demands on infrastructure.
Furthermore, complex synthetic workflows, high equipment depreciation costs, and rigorous release testing keep per‑batch costs high. Most critically, there is an upper bound to turnaround time, which leaves narrow therapeutic windows for patients with rapidly progressive malignancies.
2.2 Peptide‑Based Vaccines: An Industrial‑Friendly Technical Pathway
Peptide vaccines adopt a fundamentally different technical approach. Peptides are short amino‑acid chains produced via chemical synthesis, offering advantages in structural definition and batch‑to‑batch consistency.
Mechanistically, peptide vaccines possess unique strengths. Synthesized peptide epitopes can be directly loaded onto MHC molecules by antigen‑presenting cells for T‑cell presentation, without intracellular translation required for mRNA‑based modalities. This yields higher determinism and fewer variables.
Advantages are even more pronounced in production and distribution. Peptide vaccines do not require LNP delivery systems and exhibit well‑characterized safety profiles. Cold‑chain requirements are far less stringent; standard refrigeration suffices for storage and shipment, greatly lowering global distribution barriers. In addition, multiple neoantigen targets can be flexibly combined within a single peptide vaccine, helping counteract tumor heterogeneity and lowering relapse risk driven by loss of individual epitopes. Among domestic Chinese developers of personalized neoantigen peptide vaccines, Minkai Biomedical is one of the few innovators that has built a complete closed‑loop technology platform.
2.3 From “Quantity‑Over‑Quality” to “Precision Targeting”
The core step for neoantigen vaccines is accurate identification, from patient‑specific tumor mutations, of neoantigens capable of triggering robust immune responses. Prediction accuracy is both a prerequisite for efficacy and a major bottleneck.
Current mainstream neoantigen‑prediction algorithms achieve relatively low immunogenicity prediction accuracy, generally 20‑30% across the industry. This forces developers into a “quantity‑over‑quality” paradigm.
To address this industry pain‑point, Minkai Biomedical pursues an “IT + BT” model: integrating high‑throughput sequencing and artificial intelligence for neoantigen prediction. Its proprietary screening platform selects neoantigens that can be presented by MHC‑I / MHC‑II molecules and drive specific TCR clonal expansion, achieving >95% success rate for immunogenicity prediction.
As personalized vaccines move from small cohorts toward large‑scale clinical deployment, gaps in prediction accuracy are amplified. Higher precision eliminates non‑functional targets, optimizes immune responses, and improves clinical outcomes.
2.4 Closed‑Loop System: A Replicable Therapeutic Framework
Moderna's intismeran clinical program focuses on adjuvant treatment of resected melanoma, a tumor type characterized by high tumor mutational burden, abundant neoantigens, and inherent sensitivity to immune‑checkpoint inhibitors, which provides a sound mechanistic basis for combination therapy.
Yet the clinical landscape for tumor vaccines extends far beyond melanoma. Combination regimens, advanced refractory malignancies, and variable immune microenvironments across cancer types create far more complex clinical scenarios. Meaningful, reproducible clinical benefit in these settings cannot rely solely on vaccine administration.
Minkai Biomedical adopts a more systematic strategy, building a closed‑loop framework of “precision diagnostics‑combination therapy‑immune monitoring”. Prior to treatment, multi‑omics data combined with AI algorithms identify patient‑specific companion‑diagnostic biomarkers to stratify patients most likely to derive clinical benefit. During treatment, its GMP‑grade peptide‑vaccine manufacturing and quality‑control system enables full‑chain control from neoantigen prediction to vaccine production. Post‑treatment, efficacy‑monitoring systems track dynamic immune responses in real‑time to inform therapeutic adjustments.
The value of this closed‑loop framework lies not only in improving individual patient outcomes, but also in delivering a standardized, replicable operational blueprint for large‑scale clinical implementation.
Minkai Biomedical's investigational therapeutic personalized tumor peptide vaccine is currently at the pre‑IND stage. Its pipeline prioritizes pancreatic cancer (known as the “king of cancers”, with extremely poor survival and high post‑surgical recurrence rates), triple‑negative breast cancer (the most aggressive breast‑cancer subtype with poor prognosis), and head‑and‑neck cancer (the seventh most prevalent malignancy globally with limited personalized therapeutic options). The company intends to further expand coverage to all solid‑tumor types.
Pipeline activities are advancing steadily: workflows for genetic sequencing, neoantigen screening and in‑vitro evaluation are under construction alongside pre‑clinical studies. For regulatory strategy, the company pursues a global vision and plans to file for IND authorization with the European Medicines Agency (EMA) as a priority. Domestically, it leverages the dedicated regulatory pathway for personalized gene and cell therapies under China’s “818 New Policy” to conduct investigator‑initiated trials (IITs) and accelerate clinical translation.
A cornerstone of its global clinical strategy is its key strategic partner, the Champalimaud Foundation. A world‑renowned cancer‑research institute, its Botton‑Champalimaud Centre hosts top‑tier multidisciplinary global experts and operates state‑of‑the‑art European GMP laboratories, providing translational‑medicine support for clinical trials.
3. Chinese Manufacturing for Global Reach
Commercial bottlenecks for personalized tumor vaccines are not purely scientific; they are also supply‑chain challenges. Since each patient receives a custom‑manufactured vaccine, production speed and cost directly determine patient accessibility.
Decades of development have endowed China with a large, well‑integrated peptide‑synthesis industrial base with global competitive advantages. Notably, the commercial success of GLP‑1 therapeutics has further accelerated maturation of this supply chain. Strengths are reflected not only in ample production capacity but also in high operational efficiency. Peptide production cycles in China take two‑to‑three months, over 50% faster compared with six‑month timelines in Europe. Combined cost‑and‑efficiency advantages have the potential to transform personalized therapeutics from “lab‑based luxuries” into clinically accessible interventions.
Supported by world‑class biomedical research institutions and teams, Minkai Biomedical focuses on R&D, clinical development and commercialization of anti‑cancer personalized peptide vaccines. It delivers personalized precision immunodiagnostic and therapeutic technologies, products and regimens centered on peptide vaccines for global cancer patients. Leveraging China’s robust peptide‑manufacturing capacity, the company aims to satisfy substantial unmet clinical demand for peptide‑based tumor vaccines and achieve global commercial coverage.
4. Defining the Future of Precision Tumor Immunology
The rise of neoantigen therapeutics relies on breakthroughs in underlying prediction algorithms, optimized clinical trial designs, and robust manufacturing capacity. Undeniably, Moderna’s positive Phase‑3 result has not only delivered proof‑of‑concept for neoantigen modalities, but also lifted valuation benchmarks for the entire tumor‑vaccine sector.
Nevertheless, the competitive landscape remains far from settled. Ample room for differentiated innovation exists across multiple technical platforms (peptide, mRNA, DNA vaccines, dendritic‑cell vaccines, etc.), diverse cancer types, different clinical stages (post‑surgical adjuvant, later‑line settings), and combination‑therapy regimens.
Within this multi‑faceted competition, peptide‑based vaccines demonstrate strong potential as a potential “end‑state” format for personalized tumor vaccines, thanks to superior combinatorial target‑selection precision, favorable systemic safety profiles, and robust scalability for manufacturing and logistics.
Against this backdrop, Minkai Biomedical’s strategic positioning is clear. Its foundation rests on global clinical collaborations with elite research institutions such as the Champalimaud Foundation; its bedrock is China’s mature, high‑capacity peptide manufacturing ecosystem; its technical moat is its industry‑leading >95% neoantigen‑immunogenicity prediction accuracy. Collectively, these elements build a complete supply‑chain spanning front‑end laboratory workflows through delivery to patients worldwide.
Moderna opened the neoantigen chapter. The peptide‑vaccine story, by contrast, may be only just beginning.
Source: BeikeBio
